| Market Capitalization (Millions $) |
1,119 |
| Shares
Outstanding (Millions) |
647 |
| Employees |
18 |
| Revenues (TTM) (Millions $) |
77 |
| Net Income (TTM) (Millions $) |
-175 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
1 |
Geron Corp
Geron Corporation is a biotech company headquartered in Menlo Park, California, United States. The company focuses on the research and development of therapies to treat cancer and various degenerative disorders. They specialize in anti-telomerase therapy, which is aimed at preventing the uncontrolled multiplication of cells. This therapy targets an enzyme called telomerase, which is responsible for the unending replication of cancerous cells.
The company's flagship product, Imetelstat, is a potent inhibitor of telomerase that has shown promising results in the treatment of blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The drug works by disabling telomerase, a key enzyme that allows cancer cells to divide indefinitely. Imetelstat has been shown to prolong survival in patients with MDS and AML, with some patients achieving complete remission.
In addition to Imetelstat, Geron has an active pipeline of drugs in development for the treatment of cancer and degenerative diseases. These include GRN510, a drug that targets breast cancer stem cells, and GRNVAC1, a therapeutic vaccine for cancer.
Geron's research also extends to degenerative diseases such as spinal cord injuries, and it has a drug in development called GRNOPC1 that targets the regeneration of damaged nerve cells in the spinal cord. This therapy aims to replace damaged oligodendrocytes in the spinal cord, which help to protect and insulate nerve cells.
Since its inception in 1990, Geron has raised more than $1 billion in funding for research and development. The company collaborates with various partners from the pharmaceutical industry and academic institutions to advance its products and pursue new therapies.
Overall, Geron Corporation is a pioneering biotech company that continues to drive innovation in the areas of cancer and degenerative disease therapy. Its portfolio of products in development and research collaborations reflect its commitment to finding new treatments for some of the world's most challenging medical conditions.
Company Address: 919 East Hillsdale Blvd. Foster City 94404 CA
Company Phone Number: 473-7700 Stock Exchange / Ticker: NASDAQ GERN
|
5.77%